|Venue||IMI Sandyford, Sandyford, Co. Dublin|
|Date||Thursday, November 14th , 2019|
|Time||10:00 am - 4:00 pm|
Our final masterclass of 2019 focuses on market access, with a particular focus on the newly launched Budget Impact Template from the NCPE along with the Rapid Review process and procedures.
Dr Aine Varley and Dr Lea Trela – who were involved in the creation of the Budget Impact Template – will be attending the masterclass along with Dr Lesley Tilson, Deputy Director of the NCPE to provide a practical, hands-on workshop walking attendees through the Template.
Topics for discussion in the masterclass include:
- Budget Impact Template:
- Introduction – background, intended use, overall model structure
- Worked examples – demonstration of the use of the Excel model
- Q&A session with the NCPE team
- Rapid Review:
- Common errors made in Rapid Review applications
- Examples of a 5 page Rapid Review
- What is used from the Rapid Review to determine whether a product will need to go through the HTA route
- Oncology drugs versus non-oncology – how does the Rapid Review differ?
- Pitfalls to avoid
- Evolution of Budget Impact models
- Data Sources & Data Modelling
- Distinction between HTA & Rapid Review
This masterclass will be of particular interest to those directly involved with Market Access in their companies, along with those who need a further understanding of the process, procedures and patient impact.
Dr Lesley Tilson, Deputy Head – National Centre for Pharmacoeconomics
Lesley is the Chief Pharmacist at the National Centre for Pharmacoeconomics and is a graduate of the University of Brighton. She trained in the Chelsea and Westminster hospital, London and then worked as a resident pharmacist at the Oxford Radcliffe Hospitals NHS Trust. During this time she completed a Diploma in Clinical Pharmacy with Cardiff University.
Lesley worked as a senior clinical pharmacist at St James’s Hospital Dublin, on the intensive care unit and cardiac surgery ward. She has a PhD from the Department of Pharmacology and Therapeutics, Trinity College Dublin and a Diploma in Statistics from Trinity College Dublin.
She is a lecturer in pharmacoeconomics to undergraduate and postgraduate pharmacy students. Research interests include: Economic evaluation of pharmaceuticals in the Irish setting, pharmaceutical pricing and reimbursement strategies, policies to promote generic markets, international pharmaceutical pricing, analysis of drug utilisation and expenditure trends. Lesley received the ISPOR Bernie O’Brien New Investigator Award in May 2011.
Sandra Redmond, Managing Director – Salutem Insights
An economist by trade, Sandra has 20 years’ experience in providing expert economic reports and advice to clients. She worked as an economist in Goodbody Stockbrokers and Econtech in Australia prior to joining GSK in 2005. There, she gained lots of first-hand experience in securing reimbursement for new medicines and maintaining access for existing ones. She joined Salutem Insights as Managing Director in 2018, where she provides economic consultancy and expertise to pharmaceutical companies completing both Rapid Review and HTA submissions. She also offers other economic consultancies such as the ‘Economic Burden of Asthma’ report, published recently by the Asthma Society of Ireland.
Aisling Murphy, Senior Health Economist – Novartis
Aisling is a qualified pharmacist with over 10 years of experience across retail pharmacy and the pharmaceutical industry. She worked as a community pharmacist in the UK and Ireland; before joining Novartis as a health economist. In Novartis, she has had experience submitting rapid reviews and HTAs; along with maintaining access for reimbursed medicines. She graduated with a Master’s Degree in Pharmacy from the University of Reading, followed by a Master’s Degree in Health Economics from NUI Galway. Aisling is currently undertaking year two of an executive MBA at UCD Michael Smurfit Business School.
THIS EVENT IS NOW FULLY BOOKED
Online bookings are not available or you are logged out.